• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：恩杂鲁胺治疗转移性尿路上皮癌：关于从致命性史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症到皮肤过敏反应的不良皮肤反应临床和组织病理学谱的病例系列。

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction.

作者信息

Viscuse Paul V, Marques-Piubelli Mario L, Heberton Meghan M, Parra Edwin Roger, Shah Amishi Y, Siefker-Radtke Arlene, Gao Jianjun, Goswami Sangeeta, Ivan Doina, Curry Jonathan L, Campbell Matthew T

机构信息

Division of Cancer Medicine-Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

出版信息

Front Oncol. 2021 Mar 4;11:621591. doi: 10.3389/fonc.2021.621591. eCollection 2021.

DOI:10.3389/fonc.2021.621591
PMID:33747934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7970171/
Abstract

Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.

摘要

恩杂鲁胺是一种靶向Nectin-4的抗体药物偶联物，已被批准用于治疗在含铂化疗和免疫检查点阻断治疗后病情进展的转移性尿路上皮癌。皮肤中Nectin-4的表达可能会导致靶向性皮肤毒性。我们重点介绍了一例恩杂鲁胺输注后发生的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症，最终导致死亡。第二例描述了与恩杂鲁胺相关的多形红斑样皮疹伴界面性皮炎。详细介绍了皮肤表现、免疫组织化学研究和免疫分析。这些病例表明，一些接受恩杂鲁胺治疗的患者可能会出现灾难性后果。必须对患者进行皮肤毒性监测，皮肤科和皮肤病理学应尽早介入。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/adeacf64393d/fonc-11-621591-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/d30fbe4f0c15/fonc-11-621591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/d404f3083046/fonc-11-621591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/483c535bcf91/fonc-11-621591-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/adeacf64393d/fonc-11-621591-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/d30fbe4f0c15/fonc-11-621591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/d404f3083046/fonc-11-621591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/483c535bcf91/fonc-11-621591-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea78/7970171/adeacf64393d/fonc-11-621591-g004.jpg

相似文献

1
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction.病例报告：恩杂鲁胺治疗转移性尿路上皮癌：关于从致命性史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症到皮肤过敏反应的不良皮肤反应临床和组织病理学谱的病例系列。
Front Oncol. 2021 Mar 4;11:621591. doi: 10.3389/fonc.2021.621591. eCollection 2021.
2
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.与 Nectin-4 定向抗体药物偶联物恩福妥昔单抗相关的皮肤事件的管理。
Oncologist. 2022 Mar 11;27(3):e223-e232. doi: 10.1093/oncolo/oyac001.
3
Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma.恩扎妥昔单抗治疗转移性尿路上皮癌后出现严重皮肤药物毒性。
JAAD Case Rep. 2022 Jan 19;21:140-143. doi: 10.1016/j.jdcr.2022.01.005. eCollection 2022 Mar.
4
Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma.恩扎妥昔单抗治疗膀胱尿路上皮癌后发生的中毒性表皮坏死松解症。
IJU Case Rep. 2022 Dec 2;6(2):111-115. doi: 10.1002/iju5.12562. eCollection 2023 Mar.
5
Enfortumab Vedotin-Associated Toxic Epidermal Necrolysis-like Toxic Erythema of Chemotherapy.恩杂鲁胺相关的化疗所致中毒性表皮坏死松解症样毒性红斑
Am J Dermatopathol. 2022 Dec 1;44(12):933-935. doi: 10.1097/DAD.0000000000002255. Epub 2022 Jul 19.
6
Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic Findings.恩福妥滨药物疹：皮肤不良事件和组织病理学发现。
Am J Dermatopathol. 2024 Aug 1;46(8):538-541. doi: 10.1097/DAD.0000000000002750. Epub 2024 Jun 6.
7
Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.在接受恩杂鲁胺治疗转移性尿路上皮癌后发生的骨髓增生异常综合征。
IJU Case Rep. 2024 Jun 10;7(4):316-319. doi: 10.1002/iju5.12734. eCollection 2024 Jul.
8
A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis.恩杂鲁胺诱导的中毒性表皮坏死松解症的罕见表现。
JAAD Case Rep. 2020 Oct 23;7:57-59. doi: 10.1016/j.jdcr.2020.10.020. eCollection 2021 Jan.
9
Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System.与恩杂鲁胺相关的皮肤毒性：一项利用美国食品药品监督管理局不良事件报告系统的真实世界研究。
Front Oncol. 2022 Jan 19;11:801199. doi: 10.3389/fonc.2021.801199. eCollection 2021.
10
Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.与恩杂鲁胺治疗转移性尿路上皮癌相关的皮肤毒性。
Dermatol Online J. 2019 Feb 15;25(2):13030/qt4j44w7w6.

引用本文的文献

1
Enfortumab vedotin therapy complicated by bullous dermatitis: A case report.英弗妥单抗治疗并发大疱性皮炎：一例报告。
JAAD Case Rep. 2025 Apr 16;61:33-35. doi: 10.1016/j.jdcr.2025.03.025. eCollection 2025 Jul.
2
Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.住院患者使用恩沃利单抗和帕博利珠单抗时皮肤不良反应的识别与管理
JAAD Case Rep. 2025 Jan 28;58:85-92. doi: 10.1016/j.jdcr.2024.12.037. eCollection 2025 Apr.
3
Severe Cutaneous Toxicity in A 67-Year-Old Patient with Metastatic Urothelial Carcinoma Undergoing Therapy with Enfortumab Vedotin and Pembrolizumab.

本文引用的文献

1
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.FDA 批准概要：恩福妥单抗 Vedotin 用于局部晚期或转移性尿路上皮癌。
Clin Cancer Res. 2021 Feb 15;27(4):922-927. doi: 10.1158/1078-0432.CCR-20-2275. Epub 2020 Sep 22.
2
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症样反应的检查点抑制剂：系统评价。
Int J Dermatol. 2020 Jun;59(6):e183-e188. doi: 10.1111/ijd.14811. Epub 2020 Feb 13.
3
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
一名67岁转移性尿路上皮癌患者在接受安维汀（Enfortumab Vedotin）和帕博利珠单抗治疗时出现严重皮肤毒性。
Eur J Case Rep Intern Med. 2024 Nov 28;11(12):005003. doi: 10.12890/2024_005003. eCollection 2024.
4
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.抗体药物偶联物在泌尿生殖系统肿瘤治疗中的应用：数据更新综述。
Curr Oncol. 2024 Apr 19;31(4):2316-2327. doi: 10.3390/curroncol31040172.
5
Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: A case series and review of the literature.恩杂鲁胺致中毒性表皮坏死松解症样大疱性皮肤病：病例系列及文献综述
JAAD Case Rep. 2023 Nov 14;43:40-50. doi: 10.1016/j.jdcr.2023.10.025. eCollection 2024 Jan.
6
Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and Invasion of Bladder Cancer.莪术二酮联合吉西他滨对膀胱癌迁移和侵袭的作用及机制。
Biochem Genet. 2024 Aug;62(4):2933-2945. doi: 10.1007/s10528-023-10584-6. Epub 2023 Dec 5.
7
SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color.免疫检查点抑制剂帕博利珠单抗继发于有色人种皮肤的SJS/TEN免疫相关皮肤反应。
Gynecol Oncol Rep. 2023 Oct 7;50:101290. doi: 10.1016/j.gore.2023.101290. eCollection 2023 Dec.
8
Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma.恩扎妥昔单抗治疗膀胱尿路上皮癌后发生的中毒性表皮坏死松解症。
IJU Case Rep. 2022 Dec 2;6(2):111-115. doi: 10.1002/iju5.12562. eCollection 2023 Mar.
9
A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy.与抗癌治疗相关的大疱性皮肤不良事件综述
Biomedicines. 2023 Jan 24;11(2):323. doi: 10.3390/biomedicines11020323.
10
Nectin-4 is widely expressed in head and neck squamous cell carcinoma.黏附蛋白 4 在头颈部鳞状细胞癌中广泛表达。
Oncotarget. 2022 Oct 20;13:1166-1173. doi: 10.18632/oncotarget.28299.
帕博利珠单抗致转移性宫颈鳞癌患者史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症 1 例报告
Am J Dermatopathol. 2020 Apr;42(4):292-296. doi: 10.1097/DAD.0000000000001527.
4
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.在铂类和抗程序性死亡 1/程序性死亡配体 1 治疗后，依维莫司丁治疗尿路上皮癌的关键试验。
J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29.
5
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.厄达替尼治疗局部晚期或转移性尿路上皮癌。
N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
6
Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.与恩杂鲁胺治疗转移性尿路上皮癌相关的皮肤毒性。
Dermatol Online J. 2019 Feb 15;25(2):13030/qt4j44w7w6.
7
Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature.采用依那西普联合静脉注射免疫球蛋白治疗史蒂文斯-约翰逊综合征快速缓解：文献复习
Dermatol Ther. 2019 Jul;32(4):e12832. doi: 10.1111/dth.12832. Epub 2019 Feb 21.
8
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.史蒂文斯-约翰逊综合征在帕博利珠单抗治疗过程后期出现。
J Oncol Pharm Pract. 2019 Sep;25(6):1520-1522. doi: 10.1177/1078155218791314. Epub 2018 Aug 7.
9
A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis.环孢素治疗史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症的荟萃分析。
J Inflamm Res. 2018 Mar 28;11:135-142. doi: 10.2147/JIR.S160964. eCollection 2018.
10
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的最新观点。
Clin Rev Allergy Immunol. 2018 Feb;54(1):147-176. doi: 10.1007/s12016-017-8654-z.